Valuation: BioNTech SE

Market Cap 21.04B 24.29B 19.89B 18.01B 33.8B 2,330B 34.06B 237B 91.34B 1,181B 91.24B 89.21B 3,768B P/E 2026 *
-14.7x
P/E 2027 * -15.4x
Enterprise Value 9.67B 11.16B 9.14B 8.28B 15.54B 1,071B 15.65B 109B 41.98B 543B 41.94B 41.01B 1,732B EV / Sales 2026 *
5.35x
EV / Sales 2027 * 6.07x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-2.20%
1 week-2.00%
Current month-4.84%
1 month+3.87%
3 months+6.49%
6 months+6.03%
Current year+1.57%
1 week 95.8
Extreme 95.8
103
1 month 91.01
Extreme 91.01
120.33
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 31/12/2017
Chief Executive Officer 61 01/06/2008
Director of Finance/CFO - 30/06/2025
Director TitleAgeSince
Chairman 56 01/06/2008
Director/Board Member 69 01/06/2008
Director/Board Member 65 31/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Sell

Chief Executive Officer

-41,000 0.0170%
10/09/26 Sell

Chief Executive Officer

-20,500 0.0085%
09/09/26 Sell

Chief Executive Officer

-36,000 0.0149%
Change 5-day change 1-year change 3-year change Capi.($)
-2.20%-2.00%-1.22%-14.48% 24.29B
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.58%-1.27%+35.46%+74.97% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+1.46%+2.25%+28.84%+14.54% 25.75B
+3.63%+4.22%+25.33%-14.56% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.39%-4.24%-9.86%+454.94% 14.09B
+1.23%-1.34%+45.86%+160.89% 14.1B
Average -0.68%-2.11%+31.65%+225.25% 28.5B
Weighted average by Cap. -0.81%-1.32%+32.49%+158.30%

Financials

2026 *2027 *
Net sales 1.81B 2.09B 1.71B 1.55B 2.9B 200B 2.92B 20.39B 7.84B 101B 7.83B 7.66B 324B 1.81B 2.09B 1.71B 1.55B 2.91B 201B 2.93B 20.46B 7.87B 102B 7.86B 7.69B 325B
Net income -1.38B -1.59B -1.3B -1.18B -2.21B -153B -2.23B -15.55B -5.98B -77.37B -5.98B -5.84B -247B -1.31B -1.51B -1.24B -1.12B -2.1B -145B -2.12B -14.77B -5.68B -73.48B -5.67B -5.55B -234B
Net Debt -11.37B -13.12B -10.75B -9.73B -18.27B -1,259B -18.4B -128B -49.36B -638B -49.3B -48.21B -2,036B -10.03B -11.58B -9.49B -8.59B -16.12B -1,111B -16.24B -113B -43.55B -563B -43.5B -42.53B -1,796B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
15/09/26 US$96.69 -2.20% 590,903
14/09/26 US$98.86 +2.20% 1,222,144
11/09/26 US$96.73 +0.34% 1,176,646
10/09/26 US$96.40 -1.76% 773,743
09/09/26 US$98.13 -0.54% 707,296
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
83.75EUR
Average target price
102.58EUR
Spread / Average Target
+22.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!